Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis. - Blauvelt A; Kircik L; Schlesinger T; Pierce E; Burge R; Behling M; Atwater AR; ElMaraghy H; Armstrong A (The Journal of dermatological treatment, 2025)